Advertisement
Mylan's Vice Chairman and CEO Robert J. Coury commented: "Notwithstandingthe obvious financial benefits that NASDAQ offers, the decision to switchMylan's listing was also driven by the fact that for quite some time a greaterportion of our total trading volume was already crossing on NASDAQ tradingfacilities. This decision, we believe, will further enhance Mylan's overallneeds and efficiencies."
Advertisement
Mylan's mandatory convertible preferred stock and 1.25% convertible notesalso will move to NASDAQ with the ticker symbols "MYLNP" and "MYLNG,"respectively.
Mylan Inc., which provides products to customers in more than 140countries and territories, ranks among the leading diversified generic andspecialty pharmaceutical companies in the world. The company maintains one ofthe industry's broadest -- and highest quality -- product portfolios,supported by a robust product pipeline; owns a controlling interest in theworld's third largest active pharmaceutical ingredient manufacturer; andoperates a specialty business focused on respiratory and allergy therapies.For more information, please visit www.mylan.com.
SOURCE Mylan Inc.
